SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Kosan BioSciences -- KOSN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (480)7/14/2004 11:33:38 AM
From: nigel bates  Read Replies (1) of 933
 
Have to get back to you on that (I had a tiny holding in Neutec as I liked the idea of fishing for MABs in people rather than mice - now trying to dig a little deeper as time allows).
Question was based on this from the Mycograb pr, and something about looking for partners in the results statement -

Moreover, hsp90 is a target molecule in a range of cancers, which are another
potential indication for Mycograb(R).  In vitro data obtained by NeuTec has
suggested possible drug combinations which could improve outcome and offer
therapeutic benefit over existing therapies in breast cancer.  NeuTec believes
there is significant potential value in Mycograb(R) for cancer indications and
plans to pursue further studies in this area.


Decent market, but immunocompetent patients only...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News